UCART19 UCART19 is one of the Cellectis’ (CLLS) lead allogeneic anti-CD19 CAR T-cell products. The word allogeneic is important as it makes …

The Week in Review #13 From the Prohost Portfolio - 1. Betting on the technology - …

All the necessities, including future plans, are being taken care of by institutions, academia and biotech …

The Week in Review #12 Answering You - Many questions still need answers in the biotech’s …

DelMar Pharmaceuticals (DMPI) -- A biopharmaceutical company focused on the development of cancer therapies provided an overview …

The Week in Review #11 A New Era - Faster than the speed of light, the management …

Yes, it is Sangamo’s (SGMO) zinc finger nuclease (ZFN) gene-editing technology, which for the first time …

A couple of days ago, Cellectis (CLLS), which uses its own proprietary gene editing technology known …

The Week in Review #10 NO CONSPIRACY THEORIES - But this is what’s happening - In …

Cabozantinib Net Revenue for Q3 is $96.4 million. Total Revenue of $152.5 million  Net Income of $81.4 million, Diluted …